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The present study was designed to determine whether there is an association of drug-induced inhibition of 
calmodulin functions, drug-induced membrane stabilization (protection against osmotic lysis), and pharmaco- 
logical effects of drugs. First, data on drugs which have been studied for both calmodulin inhibition and 
membrane antihemolysis were collected from the literature and an association of the two properties was 
established. Second, ten additional drugs were selected for study of all three properties. Four drugs, with 
known antihemolytic effects, were studied for calmodulin inhibition. One drug, which was a known 
calmodulin inhibitor, was studied for antihemolysis. Our results show that membrane-stabilizing drugs are 
usually caimodulin inhibitors, and vice versa; that drugs in certain therapeutic classes inhibit calmodulin- 
activated functions and protect against osmotic lysis; and finally, that there is a significant correlation 
( P  <0.01) in terms of potency between these two actions of drugs. Data from the literature which bear on 
these mechanisms of drug actions suggest that the interactions between drugs and calmodulin, anddrugs and 
the membrane, appear to be hydrophobic in nature. At this point, we do not know whether there is some 
causal relationship between calmodulin inhibition and the antihemolytic effect of drugs, or whether the two 
are simply a result of hydrophobic properties of drugs. Similarly, the roles of calmodulin inhibition and/or 
membrane antihemolysis in producing therapeutic efficacy are unknown. 
Introduction 
In this paper, we present evidence that drugs in 
certain pharmacological classes share two interest- 
ing properties. These properties are: (1) inhibition 
of the function of a calcium-activated protein called 
calmodulin; and (2) protection of erythrocytes 
against osmotic lysis. The classes of drugs which 
share these properties include tranquilizers, other 
neuroleptics, local anesthetics, cardiac anti- 
arrhythmic agents, and membrane anti-sickling 
agents. 
Calmodulin is a low-molecular-weight, high af- 
finity calcium-binding protein which mediates 
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many of the intracellular effects of calcium in 
eukaryotic cells [1-3]. Calmodulin has been shown 
to activate or modulate intracellularly a large series 
of proteins in a calcium-dependent manner, in- 
cluding the (Ca2++Mg2+)-ATPase [3], cyclic 
nucleotide phosphodiesterase [1,2] and, adenylate 
cyclase [4,5]. As indicated above, many drugs from 
the therapeutic classes mentioned inhibit calmodu- 
lin-activated functions [6-12]. 
The second associated characteristic of these 
drugs is their effect on membrane antihemolysis. 
We have observed that a large number of drugs 
which produce calmodulin inhibition also have a 
membrane-stabilizing effect on human erythro- 
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cytes. This characteristic, which was studied in the 
1960's primarily by Seeman and his colleagues 
[13-15] was suggested to involve an expansion of 
the membrane, since the measured increase in 
membrane area was found to be considerably in 
excess to that calculated for simple physical dis- 
placement by drug molecules. More recently it was 
shown that an expansion of membrane surface 
area is accompanied by a decrease in membrane 
thickness, and that the increase in membrane 
volume is approximately equal to the volume of 
drug molecules occupying it [16]. 
In this paper we attempt to pull together the 
literature related to these topics, and add addi- 
tional data of our own. Then, in the discussion, we 
cover possible explanations for these associations. 
A preliminary communication of this work was 
presented at the Meetings of the Central Society 
for Clinical Research, Chicago, 1980, and ab- 
stracted in Clin. Res. 28 (1980) 759A. 
Materials and Methods 
Calcium adenosine triphosphatase (Ca2 + -A TPase) 
assay of 310 mosM imidazole (1-310) erythrocyte 
membranes 
All blood was drawn by venipuncture of healthy 
laboratory personnel and collected into heparin- 
ized vacutainers, and membranes were prepared 
by a slightly modified method of Farrance and 
Vincenzi [17,18]. This method was selected because 
it promotes the binding of calmodulin to the Ca 2÷ 
-ATPase and results in a high level of Ca-ATPase 
activity in the absence of added calmodulin. Red 
blood cells from about 20 ml whole blood were 
washed three times in 0.154 M NaCI, then lysed in 
0.151 M (310 mosM) imidazole buffer containing 
30/~M EDTA (pH 7.4) for 20 min at 0-5°C.  The 
lysate was spun at 4 9 0 0 0 × g  for 20 min, the 
supernatant was decanted and the membranes 
washed three times, twice with 40 ml 0.01 M im- 
idazole buffer (pH 7.4), once with 40 ml 40 mM 
histidine/40 mM imidazole buffer (pH 7.1), and 
each wash spun at 49000 × g for 20 min. The 
resulting membrane pellet was diluted with an 
equal volume of 40 mM histidine/40 mM im- 
idazole buffer (pH 7.1) and the protein concentra- 
tion determined by the method of Lowry et al. 
[ 19]. Red blood cell 1-310 membrane Ca 2÷ -ATPase 
was assayed by suspending sufficient membrane 
preparation to produce 1 mg/ml  membrane pro- 
tein in a solution containing final concentrations 
of 50 mM NaC1, 120 mM KC1 3 mM MgC12, 50 
#M CaC12, 3mM ouabain, an appropriate amount 
of drug dissolved in 40 mM histidine/40 mM 
imidazole buffer (pH 7.1) and the last ingredient 
added, 3 mM adenosine triphosphate (ATP) (pH 
7.2) all brought up to a final volume of 3 ml. For 
no-drug controls, sufficient 40 mM histidine/40 
mM imidazole buffer was added to replace the 
volume of buffer used for the drug solution to 
bring the final volume up to 3 ml. In the presence 
of ouabain and 50/~M CaC12, 90% or more of the 
ATPase activity is due to Ca2+-ATPase. The re- 
maining 10% or less, which is due to Mg 2+- 
ATPase, is not stimulated by calmodulin and does 
not significantly alter the results [3]. The tubes 
were incubated in a water bath at 37°C for 1 h, 
during which time two 0.5 ml aliquots were taken, 
the first immediately following the addition of the 
last ingredient, ATP, the second after 60 min 
incubation. Since Ca2+-ATPase activity is linear 
with time of incubation [3], additional aliquots 
were not collected. The aliquots were immediately 
mixed with 2.0 ml 6.7% trichloroacetic acid and 
immediately stored at - 7 0 ° C  until assayed for 
ATP. ATP was assayed using a modified method 
of Sigma Technical Bulletin No. 366-UV. In the 
ATP assay, as used, 0.5 M triethanolamine was 
substituted for water as one of the solvents for 
nicotinamide adenine dinucleotide (NADH). Tri- 
ethanolamine stabilized N A D H  against oxidation 
prior to the onset of the reaction. For the assay of 
Ca2+-ATPase activity, the consumption of ATP 
was employed rather than the production of in- 
organic phosphorus, because of our finding that 
drugs precipitated during the phosphorus assay, 
possibly due to formation of complexes with rea- 
gents used. Concerning possible decomposition of 
ATP during incubation at 37°C for 1 h, pre- 
liminary experiments under comparable condi- 
tions in the absence of Ca 2+-ATPase have shown 
that the amount of ATP decomposed was less than 
5% and did not significantly alter the results. 
Phosphodiesterase assay 
Cyclic nucleotide phosphodiesterase activity was 
determined following a slightly modified method 
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of Filburn and Karn [20] which is based on the 
conversion of 3H labeled cAMP to 5'AMP by 
phosphodiesterase, then the conversion of the re- 
action product, 5'AMP, to adenosine and in- 
organic phosphate by 5'-ribonucleotide phos- 
phohydrolase (5'-nucleotidase). The adenosine, 
which has the 3H label, is separated from the 
reaction mixture by alumina columns. The labeled 
adenosine is then counted in a scintillation coun- 
ter. Phosphodiesterase as a crude preparation was 
prepared from bovine brain by the method of Klee 
and Krinks [21]. A crude preparation was used 
because further purification results in the degrada- 
tion and instability of the enzyme. Calmodulin 
was purified from bovine brain by the method of 
Dedman et al. [22] to apparent homogeneity as 
shown by the formation of a single band on poly- 
acrylamide gel electrophoresis. The standard phos- 
phodiesterase assay mixture in 100 #1 contained 50 
mM Tris-HCl buffer (pH 8.0), 5 mM MgSO4, 30 
gM CaCI 2, 0.6 mM dithiothreitol, 10 ng phos- 
phodiesterase preparation, 1 #g calmodulin, an 
appropriate amount of drug dissolved in 40 mM 
histidine/40 mM imidazole buffer (pH 7.1) and 20 
gM cAMP (0.2 mCi [3H]cAMP per assay). A 
larger amount of calmodulin than necessary to 
produce maximal stimulation of phosphodiesterase 
was used to make sure calmodulin was present in 
excess. The following controls, with final volumes 
of 100 gl, were run with each assay. Nonspecific 
production of adenosine from [3H]cAMP was de- 
termined by employing control tubes containing 
all ingredients except phosphodiesterase, calmodu- 
lin and drug. Baseline phosphodiesterase activity 
(noncalmodulin-activated) was measured by in- 
cluding tubes containing all ingredients except 
calmodulin and drugs. Maximally stimulated 
phosphodiesterase activity was determined by 
measurements on tubes containing all ingredients 
except the drugs. The reaction was started with the 
addition of [3H]cAMP to each tube. The tubes 
were incubated in a water bath at 37°C for 10 
min, afterwards in a dry bath at 95°C for 1 min 
and then placed on ice. 0.01 unit of 5'-nucleotidase 
(from snake venom) was added and the tubes 
incubated in a water bath at 37°C for 30 rain. The 
reaction was terminated by the addition of 400 #1 
of 0.018M ammonium acetate buffer (pH 4.0). 
The contents of each tube were eluted over a 
colunm containing 2 ml grade I alumina (ICN 
High Grade Alumina) and collected in a scintilla- 
tion vial. Each column was washed down with 1.5 
ml 0.018M ammonium acetate buffer (pH 4.0) 
and the wash eluant from each column was col- 
lected into the same scintillation vial containing 
the sample from that column. 13.5 ml aqueous 
counting scintiUant was added to each vial and the 
samples counted in a Beckman Liquid Scintillation 
Counter (L800100). 
Osmotic lysis as determined by release of hemo- 
globin 
Osmotic hemolysis of red blood cells in the 
presence of drugs was measured following the 
method of Seeman and Weinstein [13]. An 
erythrocyte suspension was prepared from freshly 
drawn human blood in a heparinized vacutainer 
by centrifuging 0.925 ml whole blood (+ 0.075 ml 
heparin initially present in the tube) at 1500 × g 
for 5 min. The plasma and buffy coat were re- 
moved, and the erythrocytes suspended in 145 mM 
NaC1 in 10 mM sodium phosphate buffer (pH 7.0) 
or 145 mM NaCl in l0 mM Hepes buffer (pH 7.0) 
for a final volume of 12.5 ml. The choice of red 
cell suspension buffer depended on which buffer 
was used as the solvent for a drug. Drugs were 
dissolved in a solution composed either of 60.6 
mM NaC1 in l0 mM sodium phosphate buffer or 
in some cases, if solubility of a drug was a prob- 
lem, 60.6 mM NaC1 in 10 mM Hepes buffer (pH 
7.0). It was shown in preliminary work that the 
choice of buffer did not affect the results. 0.1 ml 
erythrocyte suspension and 1.5 ml drug solution 
were combined, mixed and allowed to sit at room 
temperature (23°C) for 5 rain and then centrifuged 
for 45 s at 1500 × g. The hemoglobin content of 
the supernatant was measured by recording the 
absorbance at 543 nm in a spectrophotometer. 
Drugs and reagents 
Drugs used in this study were obtained from 
the following sources: procaine and quinidine from 
the University of Michigan Hospital Pharmacy; 
dibucaine from Ciba Pharmaceutical Co.; 
thioridazine from Sandoz Pharmaceuticals; cetiedil 
from Innothera, Arceuil, France; propranolol, pro- 
cainamide, and zinc from Sigma Chemical Co.; 
UM 272 (1-dimethyl-isopropylaminc~3-[1-naph- 
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thyloxy]-propan-2-ol) and UM 424 (1-dimethyliso- 
propyl-amino-3-[2-phenylphenoxy]-propan-2-ol) 
from Dr. Lucchesi, Department of Pharmacology, 
University of Michigan. [3H]cAMP was obtained 
from New England Nuclear. All other substances 
used were reagent grade. 
Results 
Coincidence of calmodulin inhibition and membrane 
antihemolysis based on the literature 
As described in the Introduction, the focus of 
this paper is on two properties, erythrocyte mem- 
brane antihemolysis and calmodulin inhibition, 
which a group of pharmacologically diverse drugs 
share. Although these properties of drugs have 
been studied independently by various investiga- 
tors, no systematic attempt appears to have been 
made to see if they are related. We have compiled 
data from the literature on drugs which have al- 
ready been shown to produce either membrane 
antihemolysis or inhibition of calmodulin-activated 
functions. In Table I, we have listed the eight 
drugs on which both types of study have been 
done, along with appropriate references, and seven 
of the eight drugs show both properties. To our 
knowledge, the literature shows only one exception 
to the association of these properties: D-lysergic 
acid diethylamide causes membrane antihemolysis, 
but does not inhibit calmodulin-activation of 
phosphodiesterase. Four of the drugs have been 
studied for calmodulin binding and all four have 
been found to be positive (Table I). 
Coincidence of calmodulin inhibition and membrane 
antihemolysis based on our studies 
Based on the premise that membrane antihe- 
molysis, calmodulin inhibition, and certain types 
of therapeutic activity of drugs are related, and in 
general, predictive of one another, we have selected 
additional drugs for study according to the follow- 
ing criteria: (1) four drugs which are known to 
stabilize membranes against osmotic lysis for de- 
termination of their calmodulin inhibitory proper- 
TABLE I 
C O M P A R I S O N  OF PUBLISHED DATA ON D R U G - I N D U C E D  INHIBITION OF C A L M O D U L I N  F U N C T I O N S  A N D  
M E M B R A N E  ANTIHEMOLYSIS  
Class of drug Drug Calmodulin inhibition a Membrane Calmodulin 
antihemolysis b binding 
Enzyme 150 (t~M) Ref. C50 (/~M) Ref. Result Ref. 
Phenothiazine Chlorpromazine AC 200 6 10 15 + 11 
CaATPase 22,54 7,8 
PDE 6,42 9,10 
Fluphenazine CaATPase 10 7 4 15 
Trifluoperazine CaAPTase 9,50 7,23 1.2 15 + 11 
PDE 10 10 
Thioridazine PDE 18 10 0.5 15 
Promethazine PDE 340 10 16 15 
Butyrophenone Haloperidol PDE 41,60 20,11 22 15 + 11 
Tricyclic 
antidepressant  Imipramine PDE 125 11 10 15 + 11 
Halucinogen D-lysergic acid 
diethylamide PDE no effect 10 30 15 
a Calmodulin-activated functions for which data are available are adenylate cyclase (AC), erythrocyte Ca2+-ATPase (CaATPase) and 
cyclic nucleotide phosphodiesterase (PDE). ls0 refers to the concentration of the drug which inhibits 50% of the calmodulin-activated 
enzyme activity. More than one 150 value per enzyme is listed for some drugs and reflects variations in experimental conditions 
employed by different investigators. 
b C5 ° refers to the concentration of drug which causes 50% antihemolysis of human  erythrocytes. 
ties; (2) one drug which is a known calmodulin 
inhibitor, for determination of its membrane anti- 
hemolytic property, and; (3) five drugs which be- 
long to specific therapeutic classes, for determina- 
tion of either or both calmodulin inhibition and 
membrane antihemolysis. The two properties of 
calmodulin examined were calmodulin-activation 
of Ca2÷-ATPase and cyclic nucleotide phos- 
phodiesterase. All drugs studied are reported here; 
the following data have not been preselected. 
Drugs selected for study of calmodulin inhibition 
because they were known membrane antihemolytic 
agents. It can be seen in Table IIA that the four 
drugs, dibucaine, procaine, propranolol, and pro- 
cainamide, which are known from Seeman's work 
to have an antihemolytic effect on membranes and 
to produce membrane expansion, also inhibit 
calmodulin-activated Ca2÷-ATPase and phos- 
phodiesterase activities. (See also Fig. 1 for results 
on dibucaine). The concentrations of drugs at 
which 50% Ca2+-ATPase activity was inhibited 
(150) are given in Table IIA. Two substances, 
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barbital sodium and triethanolamine, were run as 
controls and even at high concentration ranges 
(1-100 mM) had little effect on Ca2÷-ATPase 
activity. 
The  I50 va lues  for i nh ib i t i on  of  
calmodulin-activated phosphodiesterase activity by 
three of these drugs are also given in Table IIA 
(propranolol was not determined). In the absence 
of added calmodulin, these three drugs inhibited 
phosphodiesterase only slightly (about 5%). 
Drug selected for study of membrane antihemoly- 
sis because it was known to inhibit calmodulin func- 
tions. Earlier work in this laboratory has shown 
that zinc is an inhibitor of calmodulin-activated 
Ca2+-ATPase and phosphodiesterase activities 
[22,23]. The present study (Table IIB and Fig. 2), 
shows that zinc also protects membranes against 
osmotic lysis. The Cs0 value for zinc is 190/~M. 
The control substances for membrane antihe- 
molysis, MgSO 4, CaC12 and NaC1 had no effect 
on the erythrocyte membrane in the range of con- 
centrations at which zinc and other drugs (dis- 
TABLE II 
Drugs selected according to three criteria were observed for their effects on either or both calmodulin inhibition and membrane 
antihemolysis. These criteria are listed as A,B and C below. The fourth category of drugs, category D, was selected for study of 
Ca2+-ATPase activity because of existing data on inllibition of PDE activity and membrane antihemolysis by these drugs. All of the 
data listed are from our study, except where indicated by parentheses. The values in parentheses are from literature sources as 
referenced. ND, not determined. 
Mode of selection of drug Drug Calmodulin inhibition Membrane antihemolysis 
results (15o, #M) results (C5o, pM) 
CaATPase PDE 
A. Known membrane antihemolytic Procaine 1400 5 000 (400000)[14] 
agent Dibucaine 2 500 520 ( 100)[14] 
Procainamide 40 000 30 000 (5 000)[15[ 
Propranolol 5 000 N.D. (250) 151 
B. Known calmodulin inhibitor Zinc (40) t251 (75) TM 190 
C. - Therapeutic class 
(1) Membrane antisickler Cetiedil 800 800 45 
(2) Antiarrhythmic agent Quinidine 1000 1000 450 
UM 272 N.D. N.D. 240 
UM 424 N.D. N.D. 350 
Bretylium tosylate N.D. N.D. no effect 
Imipramine 1000 (125)0 II (0.5)051 
Thioridazine 72 (18) It°] (10) 0~1 
D. Known membrane antihemolytic 
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Fig. 1. Inhibition by cetiedil, quinidine, and dibucaine of 
calmodulin activated Ca2+-ATPase activity of 310 mosM im- 
idazole erythrocyte membranes ( - - - - - )  and calmodulin- 
activated phosphodiesterase activity ( ). 
cussed below) were effective (Fig. 2). 
Drugs selected for study of either or both 
calmodulin inhibition and membrane antihemolysis 
because of therapeutic class. Five additional agents 
from two therapeutic classes (Table IIC) were 
studied to see if the therapeutic class of a drug is 
predictive of its actions on calmodulin functions 
and membrane stabilization. The two therapeutic 
classes are: (1) membrane antisickling agents rep- 
resented by the drug cetiedil, and (2) cardiac anti- 
arrhythmic agents represented by the drugs 
quinidine, bretylium tosylate, and two University 
of Michigan experimental drugs, UM 272 and UM 
424. 
Two of the five drugs were observed for inhibi- 
tion of calmodulin-activated functions. It can be 
seen in Fig. 1 and Table IIC that cetiedil and 
quinidine inhibit calmodulin-activated Ca 2÷- 
ATPase and phosphodiesterase activities. The 150 
values are given in Table IIC. 
All five drugs were tested for membrane antihe- 
molysis and four were found to be positive (Table 
IIC and Fig. 2). The (?50 values for these four drugs 
are given in Table IIC. The fifth drug, bretylium 
tosylate, had no effect on membrane antihemoly- 
sis. The controls employed in determination of 
membrane antihemolysis have already been dis- 
cussed above. 
Test of the quantitative relationship between 
calmodulin inhibition and membrane antihemolysis 
Earlier, we have stated that the two properties 
of drugs, that is, membrane protection against 
osmotic lysis and calmodulin inhibition, may be 
related and, in general, predictive of one another, 
and data to support this view have been presented 
in Tables I and II. Further support for this rela- 
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Fig. 2. Protection of erythrocytes against osmotic lysis by zinc, cetiedil, quinidine, UM 272, UM 424. The control substances are 
MgSO4, CaC12 and NaCI. The reduction in osmotic lysis of erythrocyte membranes caused by drugs is expressed as a proportion of 
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Fig. 3. Relationship between Ca2+-ATPase inhibition and 
membrane antihemolysis. The inhibitory concentrations of 
drugs are negative logarithmic transformations of the/5o and 
C5o values expressed in molar concentrations of drugs pre- 
sented in Table I and II. Q, our values; ×,  literature values; 
PRO, procaine, PA, procalnamide; QUIN, quinidine; PROPR, 
propranolol; DB, dibucaine; ZN, zinc; CET, cetiedil; IMI, 
imipramine; CPZ, chlorpromazine; FPZ, fluphenazine; TFP, 
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Fig. 4. Relationship between phosphodiesterase (PDE) inhibi- 
tion and membrane antihemolysis. The inhibitory concentra- 
tions of drugs are negative logarithmic transformations of the 
13o and C5o values expressed in molar concentrations of drugs 
presented in Tables I and II. O, our values; ×,  literature 
values. All abbreviations used for drugs are listed in the legend 
to Fig. 3 except two. These are: HAL, haloperidol; PROM, 
promethazine. 
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Figs. 3 and 4. Here we have compiled the data 
from Tables I and II and correlated each 
calmodulin-activated function with membrane an- 
tihemolysis. Where more than one I50 value per 
enzyme was listed for a drug in Table I, we have 
averaged them and used the average value. The 
correlation between the C50 values for the mem- 
brane antihemolytic effect and the 150 values for 
Ca 2+ -ATPase inhibition for the combined sample 
of drugs is 0.689 (significant at the 0.01 level; 
Fig. 3). The correlation between the C50 values for 
membrane antihemolysis and the 15o values for 
phosphodiesterase inhibition is 0.804 (significant 
at the 0.01 level; Fig. 4). Finally, the correlation 
between the 15o values of the two calmodulin- 
activated functions, Ca2+-ATPase and phos- 
phodiesterase activities, is 0.938 (significant at the 
0.01 level). 
Discussion 
Two independent sets of data are presented 
here which show that a variety of drugs from 
different therapeutic classes have parallel actions 
with respect to erythrocyte membrane stabilization 
and  inhibition of calmodulin-activated functions. 
The first set of data comes from the literature. Of 
the eight drugs which have been studied for both 
actions, seven are shown to be positive (Table I). 
These include representatives from the phenothia- 
zine, butyrophenone, and tricyclic antidepressant 
drug classes. 
The second set of data presented in this paper is 
based on our studies. Drugs were selected accord- 
ing to one of three criteria - membrane antihemo- 
lysis, calmodulin inhibition or certain therapeutic 
activities - and a remarkable degree of concor- 
dance of the three characteristics was seen (Table 
II). Four known antihemolytic drugs were shown 
to be calmodulin inhibitors (four cases of concor- 
dance of the properties). One known calmodulin- 
inhibiting drug was shown to cause membrane 
antihemolysis (one case of concordance). Two 
drugs which were selected becasuse they belong to 
specific therapeutic classes were shown to both 
inhibit calmodulin-activated functions and cause 
membrane antihemolysis (four cases of concor- 
dance). Two of three drugs, which were also 
selected because of certain therapeutic actions, 
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showed membrane antihemolysis (two of three 
cases of concordance). With the latter three drugs, 
calmodulin inhibition was not studied. Thus in 11 
of 12 opportunities, the association of therapeutic 
class, calmodulin inhibition and membrane antihe- 
molysis were found to be present. 
Our results indicate that it is possible to predict 
calmodulin inhibition if a drug has membrane 
antihemolytic properties, and vice versa. A close 
association between these properties is further sup- 
ported by highly significant correlations between 
the C50 values for the membrane antihemolytic 
effect and the 150 values for Ca2+-ATPase and 
phosphodiesterase activities for the combined data. 
What is the reason fo r  these associations? The 
first of two hypotheses we will consider is one of 
'causality' [27,28]. This hypotheses proposes, first, 
that calmodulin inhibition causes a reduction in 
osmotic lysis of erythrocyte membranes, giving 
calmodulin a role in somehow modulating mem- 
brane stabilization. According to this hypothesis, 
any drug that is a calmodulin inhibitor would also 
be a membrane antihemolytic agent, although 
membrane stabilization could occur throught 
routes other than calmodulin inhibition. A second 
part of the causality hypothesis holds that 
calmodulin inhibition results in certain kinds of 
pharmacological effects, such as membrane anti- 
sickling effects, cardiac antiarrhythmic effects, cer- 
tain central nervous system effects, and local 
anesthesia. Such a concept appears plausible be- 
cause of the knowledge that calcium has important 
regulatory roles in many cell types. For example, 
calcium is known to be intimately involved with 
platelet, spermatozoal, and neutrophil activation 
[31]. On the other hand, calmodulin inhibitors, 
such as the phenothiazines, inhibit all of these 
activations [31 ]. 
However, a number of factors mitigating against 
the causal hypothesis can be brought to bear. With 
respect to the expansion of the membrane greater 
than can be accounted for by the incorporation of 
the drug [13-15], which suggests the need for a 
modulation of membrane expansion, recent work 
has offered an explanation. Jain et al. [35] study- 
ing local anesthetics and phenothiazines, have 
shown by scanning calorimetry that membrane 
expansion is associated with a disordering of the 
phospholipid bilayer. Snow et al. [36], working 
with local anesthetics, and Krishnan and Brandts 
[37] studying alcohols and phenothiazines, have 
reported alterations of the phospholipid transition 
profile and in some cases the transmembrane pro- 
tein, called band 3. In other words, it appears that 
membrane antihemolytic drugs may disorder the 
phospholipid bilayer around the region of band 3 
protein, perhaps accounting for membrane expan- 
sion and for an increase in membrane surface area 
in relation to a decrease in membrane thickness 
[16]. These findings argue against the need to 
invoke an effect of a regulator, such as calmodulin, 
to account for this membrane effect. 
Regarding the relationship of the pharmaco- 
logic effects of drugs to calmodulin inhibition, 
recent work indicates that calmodulin inhibition is 
not involved in neuroleptic effects. Norman et al. 
[9] have studied the effect of therapeutically active 
and inactive isomers of neuroleptic drugs on the 
inhibition of calmodulin-activated phosphodiester- 
ase activity, and found that both stereoisomers of 
these drugs are equally inhibitory to calmodulin. 
Thus, calmodulin inhibition does not appear to be 
related to therapeutic efficacy with the neuro- 
leptics. Levin and Weiss [12] have found some 
stereospecificity in the binding of drug isomers to 
calmodulin; however, the difference in binding 
between isomers was small, and the significance of 
this difference is uncertain. Similar studies have 
not been carried out with other classes of ther- 
apeutic agents, and it remains possible that 
calmodulin inhibition is involved in the mecha- 
nism of action of many of these drugs. 
The second hypothesis to explain the associa- 
tions may be called the 'hydrophobic hypothesis'. 
This hypothesis holds that calmodulin binding and 
inhibition, membrane antihemolysis and certain 
kinds of therapeutic effects are all related to rela- 
tively nonspecific hydrophobic properties of drugs, 
and that this hydrophobicity is the common de- 
nominator. LaPorte et al. [38] have shown that the 
interaction between calmodulin, which reveals a 
hydrophobic domain when it binds calcium, and 
target proteins or drugs, is hydrophobic is char- 
acter. Based on these results, LaPorte et al. have 
suggested that the hydrophobic domain is the site 
of interface between calmodulin and numerous 
interacting substances including drugs and target 
proteins. It is possible that a correlation might 
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exist between the degree of hydrophobicity of a 
drug and its'potency as an inhibitor of calmodulin 
function on the one hand, and its potency as a 
membrane stabilizer on the other. Seeman [15] has 
demonstrated that relative hydrophobicity corre- 
lates with membrane antihemolytic potency. Nor- 
man et al. [9] have shown that hydrophobicity of 
neuroleptic drugs as measured by octanol/water 
partition coefficients correlates well with 150 for 
calmodulin-activated phosphodiesterase activity. A 
related study was earlier reported by Roufogalis 
[39] who showed hydrophobicity/membrane ac- 
tion relationships for various local anesthetics, 
antihistamines, tricyclic antidepressants, and phe- 
nothiazine tranquilizers. He showed a positive cor- 
relation between hydrophobicity and inhibition of 
erythrocyte membrane (Na + + K + )-ATPase. Thus, 
a hydrophobicity hypothesis could explain the 
inhibition of calmodulin, could explain membrane 
antihemolysis, and could presumably explain the 
high correlation in drug potencies producing these 
effects. 
A third possible explanation is suggested by 
recent reports that drug actions may be associated 
with the effects of drugs on the distribution of 
calmodulin within the membrane and cytosolic 
portions of cells in certain tissues. Thus a 'distribu- 
tional hypothesis' would propose that drugs indi- 
rectly modulate the calmodulin-activated enzymes 
within these compartments by virtue of these ef- 
fects [40,41]. 
The causality hypothesis is the more exciting of 
the two major proposals. However, even if rela- 
tively nonspecific hydrophobicity is the explana- 
tion for these associations, the associations will 
remain interesting and potentially useful from the 
standpoint that the presence of one effect is pre- 
dictive of the other two. That is, one might screen 
for other properties if one finds one of the three 
properties. This is exactly what we our doing in 
our efforts to find better membrane antisickling 
agents. That is, we are screening known membrane 
antihemolytic agents and calmodulin inhibitors for 
their antisickling potency. 
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